Literature DB >> 1088963

Clofibrate and niacin in coronary heart disease.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1088963

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  232 in total

1.  Lipid lowering drugs and coronary heart disease.

Authors:  P J Scott
Journal:  Drugs       Date:  1975       Impact factor: 9.546

Review 2.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 3.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

4.  Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?

Authors:  James K Liao
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

Review 5.  Fibrates for treatment of the metabolic syndrome.

Authors:  Kevin C Maki
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

Review 6.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

8.  Interconnect--the new alternative.

Authors:  R J St Onge
Journal:  Med Group Manage       Date:  1979 Mar-Apr

Review 9.  Antihyperlipidaemic agents. Drug interactions of clinical significance.

Authors:  J A Farmer; A M Gotto
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 10.  Cholesterol in patients with coronary heart disease: how low should we go?

Authors:  H B Rubins
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.